Drug updated on 4/16/2024
| Dosage Form | Injection (intravenous; 200 mg as a solid [cake or powder] in a single-dose vial for reconstitution) |
| Drug Class | Echinocandin antifungals |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of candidemia and invasive candidiasis in patients 18 years of age or older who have limited or no alternative options.
Summary
- Rezafungin (Rezzayo) is an echinocandin antifungal for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative options. It inhibits the synthesis of β-(1,3)-D-glucan, essential for the fungal cell wall.
- The effectiveness and safety of rezafungin compared to other antifungal agents were assessed through a network meta-analysis including 13 trials with 3632 patients.
- In terms of effectiveness, there were no significant differences between treatments. However, rezafungin showed higher rates of clinical and mycological responses alongside caspofungin and micafungin, with fluconazole being less effective.
- Rezafungin had lower discontinuation rates, indicating better tolerance than some alternatives like conventional amphotericin B, which has a poorer safety profile due to its potential to impair liver function.
- The study focused on adult patients aged 18 years or older with candidemia and invasive candidiasis who have limited or no alternative options. It suggests rezafungin may be suitable for a broad range of adults due to its high effectiveness and good tolerability.
- Echinocandins, including rezafungin, are recommended as first-line treatments for invasive candidiasis, while azoles and liposomal amphotericin B are suggested as second-line treatments in cases of resistance or hypersensitivity. This underscores the potential value of rezafungin in the therapeutic landscape against invasive candidiasis, pending further research to fully establish its exact placement and utility.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rezzayo (rezafungin) Prescribing Information. | 2023 | Patheon Italia S.P.A., a Thermo Fisher Scientific company, Monza, Italy |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses. | 2022 | International Journal of Antimicrobial Agents |